DNER and Thrombocytopenia: Eleven articles reported the incidence of thrombocytopenia for twelve BET inhibitors ranging from 20% to 96% (Figure 5A), and the overall and Grade≥3 event rates were 42.1% (95% CI 0.325, 0.524) and 20.3% (95% CI 0.144, 0.279), respectively (Figures 5A,B).